Literature DB >> 17250957

The Biology of Ewing sarcoma.

Nicolò Riggi1, Ivan Stamenkovic.   

Abstract

Sarcomas account for less than 10% of all human malignancies that are believed to originate from as yet poorly defined mesenchymal progenitor cells. They constitute some of the most aggressive adult and childhood cancers in that they have a high metastatic proclivity and are typically refractory to conventional chemo- and radiation therapy. Ewing's sarcoma is a member of Ewing's family tumors (ESFT) and the second most common solid bone and soft tissue malignancy of children and young adults. It is associated in 85% of cases with the t(11;22)(q24:q12) chromosomal translocation that generates fusion of the 5' segment of the EWS gene with the 3' segment of the ETS family gene FLI-1. The resulting EWS-FLI-1 fusion protein is believed to behave as an aberrant transcriptional activator that contributes to ESFT development by altering the expression of its target genes in a permissive cellular environment. Although ESFTs are among the best studied sarcomas, the mechanisms involved in EWS-FLI-1-induced transformation require further elucidation and the primary cells from which ESFTs originate need to be identified. This review will highlight some of the most recent discoveries in the field of Ewing sarcoma biology and origins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17250957     DOI: 10.1016/j.canlet.2006.12.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  104 in total

Review 1.  Targeted therapy in bone and soft tissue sarcoma in children and adolescents.

Authors:  Patrick A Thompson; Murali Chintagumpala
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

2.  Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes.

Authors:  Isaac A Klein; Wolfgang Resch; Mila Jankovic; Thiago Oliveira; Arito Yamane; Hirotaka Nakahashi; Michela Di Virgilio; Anne Bothmer; Andre Nussenzweig; Davide F Robbiani; Rafael Casellas; Michel C Nussenzweig
Journal:  Cell       Date:  2011-09-30       Impact factor: 41.582

3.  Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung.

Authors:  Zhichao Zhou; Keri Schadler Stewart; Ling Yu; Eugenie S Kleinerman
Journal:  Angiogenesis       Date:  2010-12-24       Impact factor: 9.596

4.  CAPER-α alternative splicing regulates the expression of vascular endothelial growth factor₁₆₅ in Ewing sarcoma cells.

Authors:  Gangxiong Huang; Zhichao Zhou; Hua Wang; Eugenie S Kleinerman
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

Review 5.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

Review 6.  The TET family of proteins: functions and roles in disease.

Authors:  Adelene Y Tan; James L Manley
Journal:  J Mol Cell Biol       Date:  2009-09-24       Impact factor: 6.216

7.  Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors.

Authors:  Randala Hamdan; Zhichao Zhou; Eugenie S Kleinerman
Journal:  Mol Cancer Ther       Date:  2013-11-26       Impact factor: 6.261

Review 8.  Crosstalk of Notch with p53 and p63 in cancer growth control.

Authors:  G Paolo Dotto
Journal:  Nat Rev Cancer       Date:  2009-07-16       Impact factor: 60.716

9.  CD133 expression in chemo-resistant Ewing sarcoma cells.

Authors:  Xiaohua Jiang; Ynnez Gwye; Darren Russell; Christine Cao; Dorothea Douglas; Long Hung; Heinrich Kovar; Timothy J Triche; Elizabeth R Lawlor
Journal:  BMC Cancer       Date:  2010-03-26       Impact factor: 4.430

10.  RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.

Authors:  Shilpi Arora; Irma M Gonzales; R Tanner Hagelstrom; Christian Beaudry; Ashish Choudhary; Chao Sima; Raoul Tibes; Spyro Mousses; David O Azorsa
Journal:  Mol Cancer       Date:  2010-08-18       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.